Libang Instruments (300206): Performance was lower than expected, and the impact of the epidemic was basically outstanding, compared to ultrasound and IVD performance
In-depth report by Libang Instruments (300206): The epidemic interferes with the endogenous growth of many business sectors in Qingqing
Libang Instruments (300206): Significant month-on-month improvement, impressive performance in sectors such as ultrasound, maternal and child care
Ribang Instruments (300206) 2021 Annual report comments: the performance is in line with our expected steady growth of non-epidemic products
Ribang Instruments (300206): the performance is in line with our expected epidemic situation to boost the company's expansion at home and abroad.
Ribang Instruments (300206): return to normalization, high growth and rapid rebound of non-epidemic related products
Ribang Instruments (300206): the performance is basically in line with expectations, it is necessary to continue to pay attention to the multi-point flowering of the company's product line with a substantial increase in brand power.
Ribang Instruments (300206) 2020 Annual report comments: revenue is better than we expected epidemic situation to accelerate the pace of development of the company
Comments on Ribang Instruments (300206) Quarterly report 2020: Q3 continues high-growth brand + R & D to lay the foundation for sustainable development in the future
Ribang Instruments (300206): pay attention to the rapid growth in the pure market without epidemic situation in China.
Ribang Instruments (300206): Q3 sustained high growth epidemic situation to accelerate the pace of development of the company
Ribang Instruments (300206) comment report: international medical device platform companies with better-than-expected brand power during the epidemic
Ribang Instruments (300206): the performance greatly exceeded expectations. COVID-19 's epidemic situation accelerated the company's growth.
Ribang Instruments (300206): the half-year performance exceeded expectations and contributed significantly to the overseas market.
理邦仪器(300206):2019年利润拐点进一步确立 2020Q1受疫情影响显著
理邦仪器(300206):一季度疫情调动公司供应链能力 持续关注二季度海外订单带来的增长
理邦仪器(300206):海外疫情发展超出预期有望带来更多需求 2季度经营增长有望提速
理邦仪器(300206):内生拐点+新冠疫情助力高增长 业绩进入快速释放阶段
理邦仪器(300206):一季报归母净利润增速约125%远超预期 海外疫情持续驱动公司业绩快速增长
理邦仪器(300206):受疫情刺激 2020Q1业绩大幅增长
No Data
No Data